Figure 3From: Modulation of deoxycytidine kinase (dCK) and glycogen synthase kinase (GSK-3β) by anti-CD20 (rituximab) and 2-chlorodeoxyadenosine (2-CdA) in human lymphoid malignancies Survival of WSU-WM-bearing ICR-SCID mice treated with 2-CdA, RTX alone or in combination. Log-Rank Test showing the combination (RTX +2-CdA) to be statistically superior to single agents (p = 0.01007).Back to article page